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Running title: 
Reproductive medicine: still more ART than science? 
 
The history of obstetrics and gynaecology is not a tale of evidence-based practice. Tradition, 
expert opinion, and the lure of new technology have frequently superseded evidence as the 
primary driver for clinical decision making 1. The proof can be found in a litany of dubious 
interventions which have gained widespread popularity despite an absence of high quality 
data attesting to their effectiveness and, in some cases, ample credible evidence 
demonstrating harm. As a specialty, we have relied on investigations including X-ray 
pelvimetry and antenatal stress tests, subjected innumerable women to stilboestrol and 
thalidomide, and have performed routine episiotomy in all primigravid women 1, . It is no 
surprise that, in 1979, Archie Cochrane famously awarded obstetrics the ‘wooden spoon’ for 
being the least evidence-based specialty. 
 
Reproductive medicine has come a long way since then and there have been dramatic 
advances in the field such that biological parenthood is a reality for many couples, for whom 
adoption was the only available route in the past. The gold standard in reproductive 
medicine is now “to provide childless couples with the best possible management of their 
fertility problems, while at the same time ensuring that they are not exposed to unnecessary 
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risks or ineffective treatments”3. In order to achieve this standard, we need reliable evidence 
which can be used to develop clinical practice guidelines. Unfortunately, even where we 
have good evidence, its uptake is far from universal1. This is particularly true in the field of 
assisted reproduction, which has become increasingly commercialised with a pronounced 
predilection for overdiagnosis, overuse, and overtreatment. 
 
Too much treatment? 
One in seven couples will struggle to conceive within a year, and will be labelled as infertile. 
Yet, population based data show that half of this group will go on to conceive in the next 12 
months 5. Meanwhile, success rates for fertility treatments remain modest, with live birth 
rates for in vitro fertilisation (IVF) estimated to be in the region of 27% per treatment cycle 
(https://www.hfea.gov.uk/media/2563/hfea-fertility-trends-and-figures-2017-v2.pdf). Yet, 
media fuelled unrealistic expectations on the part of couples coupled with skilful marketing 
by commercial fertility clinics has caused a global explosion in the use of assisted 
reproductive technology. As few governments fund infertility treatment the private sector is 
buoyant. Contrary to guidelines, assisted reproductive technology is frequently initiated 
early-on in couples who still have a reasonable chance of conception, promoting 
overtreatment, increasing avoidable harm, and increasing healthcare costs 4. A plethora of 
essentially unproven add-on interventions are offered to couples in a technological arms 
race between fertility clinics 7. Since financial considerations often influence treatment 
policies, the novelty and apparent sophistication of these new technologies take precedence 
over proof of effectiveness and safety. For many couples, the additional expense of add-on 
therapies is itself interpreted as a sign of quality. It is the perfect storm for exploitation. 
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The gap between clinical practice and evidence 
While the absence of evidence in many areas of reproductive medicine remains a problem, 
blatant disregard for evidence which is available is an inexcusable but all too common 
phenomenon. One of the most notable and regrettable examples of ignoring evidence in 
assisted reproductive technology is the persistent practice of transferring two or more 
embryos at a time. This option appears attractive to many couples, who see it as a means to 
maximise their chances while obviating the need for further treatment to have a second 
child. Some IVF clinics continue to support this practice on grounds of patient autonomy, 
whilst downplaying the considerable maternal, fetal, neonatal, and childhood risks 
associated with multiple pregnancy. Although multiple pregnancy is almost completely 
preventable by the practice of single embryo transfer, many healthcare providers across the 
United Kingdom, Europe, and North America continue to transfer multiple embryos. One 
explanation is that IVF is often self-funded whilst maternity and neonatal care are often 
covered by the state or by insurance companies. If the same funder paid not only for IVF but 
also for maternity and neonatal care, then there would be a strong incentive to reduce 
multiple pregnancies in order to avoid increases in fetal, neonatal, and childhood morbidity 
and the attendant costs. In 2005, New Zealand increased funding for IVF from one cycle to 
two provided that a single embryo transfer strategy was used. As a result, New Zealand now 
has the lowest rate of IVF-related multiple pregnancies (4%) in the world 
(https://npesu.unsw.edu.au/surveillance/assisted-reproductive-technology-australia-and-
new-zealand-2015). 
 
Another example where common practice defies the evidence is the expansion of intra-
cytoplasmic sperm injection (ICSI), originally designed for men with very poor semen quality, 
to include couples where the semen parameters are normal. Indeed, it has now become the 
dominant form of in vitro fertilisation in many countries. The Cochrane review of in vitro 
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fertilisation versus intra-cytoplasmic sperm injection for non-male infertility includes a single 
randomised trial involving 415 couples which reported 70/213 ongoing pregnancies following 
in vitro fertilisation compared to 51/202 in the intra-cytoplasmic sperm injection group (Odds 
ratio 1.44, 95% confidence interval 0.95 to 2.21) 11. Data from a subsequent Canadian study 
which randomised 60 women with unexplained infertility to in vitro fertilisation or intra-
cytoplasmic sperm injection failed to show a statistically significant difference in live birth rate 
12
. In this context it is the focus on a surrogate outcome (fertilisation rate) rather than the 
clinical outcome (live birth) which has presumably influenced clinical decision making; trials 
of randomised oocytes suggest that a strategy of ICSI in non-male infertility could reduce the 
number of cases of total fertilisation failure, but an improvement in live births has not been 
demonstrated. Similarly, preimplantation genetic testing and time lapse systems for embryo 
incubation are becoming routine practice in many clinics, despite a lack of robust evidence of 
clinical benefit 13, 14. 
 
Marketing trumps informed patient choice 
The primary criterion used by many people with infertility to select an IVF clinic is its success 
rate. In order to be competitive, fertility clinics must convince couples that the path to 
parenthood leads through their doors. But there is a clear tension between direct to 
consumer advertising of assisted reproductive technology and informed patient choice. 
Clinics frequently wield emotive language and creative statistics to persuade rather than to 
inform 16, 17. Websites speak of ‘dreams’ and ‘miracles’16, while bespoke success rates can 
be constructed from a large array of statisticsin order to cast a clinic’s performance in a 
favourable light 17. Due to a lack of binding standards on assisted reproductive technology 
outcome reporting, couples may be misled about the likelihood of success and may compare 
clinics on the basis of incomparable figures. Self-regulation does not appear to furnish 
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couples with impartial information regarding the effectiveness of different treatment 
interventions. 
 
Challenges for evidence-based assisted reproductive technology 
Before being implemented as routine, any assisted reproductive technology intervention 
should undergo preclinical and clinical trials, followed by randomised controlled trials (RCTs) 
to prove efficacy and safety, with long-term follow up to evaluate ongoing effectiveness and 
safety 7. However, in assisted reproductive technology, eagerness to identify attractive new 
interventions has led to a quantity over quality approach to RCTs. Consequently, the clinical 
effectiveness of interventions is often not robustly assessed. A pivotal limitation is the size of 
the trials undertaken. In order to achieve 80% power to detect an improvement in birth rate 
from 27% to 32% at a 5% significance threshold, a trial size of 2,610 women is required. 
This far exceeds the numbers of women we actually see in the vast majority of in vitro 
fertilisation trials. Routinely collected data and large electronic databases have been touted 
as a solution but the absence of random allocation introduces doubt regarding the accuracy 
of any conclusions drawn. These are essentially large-scale observational studies, and do 
not offer a free pass to assisted reproductive technology treatment evaluation.  
 
In principle, the machinery of meta-analysis offers a means to overcome the limitations of 
small individual trials, but this is predicated on sufficient cumulative sample sizes after 
pooling studies. The trend to ‘test’ many interventions in small trials does not guarantee this 
will hold. Moreover, if trials do not report outcomes in a consistent fashion, meta-analysis is 
precluded. Recent reviews of reporting standards in this field suggest that they do not 18. 
Moreover, many trials measure outcomes in such a way that the benefits of randomisation 
are lost, and many fail to report cumulative birth rates per couple, which is probably the most 
relevant outcome for patients. The need to establish statistically valid, patient-centred 
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outcome measures is the motivation behind the Core Outcome Measures for Infertility Trials 
(COMMIT) project, which will establish core outcomes to be reported in all assisted 
reproductive technology trials 
(https://www.phc.ox.ac.uk/research/hypertension/pregnancy/commit). Fewer, larger RCTs 
developed through priority-sharing partnerships and enabled by clinical trial networks 
committed to the use of common reporting standards will ensure high quality evidence with 
maximum clinical utility. A new priority setting partnership has been established for infertility 
aiming to bring together professionals, researchers, and people with infertility to prioritise 
unanswered research questions (www.phc.ox.ac.uk/infertility). In Table 1, we present our top 
ten research gaps in reproductive medicine.  
 
Conclusions:  
How to introduce new technologies in reproductive medicine responsibly? 
With respect to new assisted reproductive technologies, our responsibility extends beyond 
the couples we treat to the wellbeing of future generations. Under the status quo however, 
robust evidence of effectiveness and safety is not a prerequisite for adoption of novel 
interventions[added Harper 2017 here]. One solution to the trend for treatment to be 
delivered in defiance of evidence would be stronger regulatory standards governing the 
introduction of new therapies in assisted reproductive technology. A study on the 
acceptability of regulating such techniques found broad support from clinicians, patients and 
the general public for regulation of new reproductive technologies by a national bioethics 
committee, which would consult with advisors from various backgrounds 24. We are not 
sympathetic to the argument that a requirement for rigorous prospective treatment 
evaluation would impede progress in the field, since it is not at all clear that a ‘right to try’ 
philosophy, where treatments are sold to vulnerable people on a speculative basis, benefits 
anyone other than the people making the sale, and may well cause harm. Until the time 
comes when we insist that generation of evidence precedes implementation of new 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
technologies rather than follows it, reproductive medical research will be largely preoccupied 
with reversing perverse practice. We believe that this ongoing need for medical reversal in 
reproductive medicine is the real enemy of progress.  
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Table 1: Ten research gaps in reproductive medicine 
 
Population Interventions 
In women with unexplained 
subfertility 
What is the effect of  IVF versus expectant management 
In men with azoospermia and 
severe oligospermia 
What is the evidence for available screening tests (e.g. genetic testing, 
ultrasound, screening for cancer, others) 
In women with repeated IVF 
failure   
What is the effect of different treatment adjuncts such as  endometrial 
scratch, hysteroscopy, immunoglobulin, G-CSF 
In women having IVF who are 
undergoing frozen embryo 
cycles 
What is the optimal regimen (e.g.  endometrial preparation, triggering, 
luteal phase support) 
 
In women having IVF and 
undergoing final oocyte 
maturation 
What is the effect of Gn RhA trigger versus HcG trigger 
In men with reduced semen 
quality 
What is the most optimal treatment modality in relation to the semen 
quality (expectant management, IUI, IVF or ICSI) 
In women having IVF What is the effect of cleavage stage versus blastocyst transfer 
In women having IVF What  is the optimal culture environment 
In women having IVF and their 
children 
What is the long term effect (over > 20 years) 
In women having IVF What is the optimal embryo selection method (morphology, genetic 
testing (PGS), time-lapse algorithm)?  
 
 
 
